On April 25, 2019 IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx"), a leading oral drug delivery company, reported that its Executive Vice-President and Chief Financial Officer, Andre Godin, is scheduled to present at the 2019 Bloom Burton & Co. Healthcare Investor Conference on April 30, 2019 at 2:30 p.m. ET at the Metro Toronto Convention Centre (Press release, IntelGenx, APR 25, 2019, View Source;Co-Healthcare-Investor-Conference/default.aspx [SID1234535416]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mr. Godin will provide an overview of IntelGenx’s business during the presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

The presentation will be webcast live and archived for 90 days on the Company’s website, at www.intelgenx.com, under "Presentations".

On April 25, 2019 GlycoMimetics, Inc. (NASDAQ: GLYC) reported that it will host a conference call and webcast to report its first-quarter 2019 financial results on Thursday, May 2, 2019, at 8:30 a.m. ET (Press release, GlycoMimetics, APR 25, 2019, View Source [SID1234535415]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The dial-in number for the conference call is (844) 413-7154 (U.S. and Canada) or (216) 562-0466 (international) and entering passcode 1096657. To access the live audio webcast, or the subsequent archived recording, visit the "Investors – Events & Presentations" section of the GlycoMimetics website at www.glycomimetics.com. The webcast will be recorded and available for replay on the GlycoMimetics website for 30 days following the call.

On April 25, 2019 Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer reported that it will present at the Neosynth Breast Cancer Conference in Boston MA on April 24-25th 2019 (Press release, Andarix Pharmaceuticals, APR 25, 2019, View Source [SID1234535414]).
The presentation will address the ability of theranostic technology to provide personalized medicine to diagnose and treat breast cancer. The three main types of breast cancer are defined by specific biomarkers and are over-expressed in the disease. The Andarix drug Tozaride targets somatostatin receptors on breast cancer cells and represents a new target for breast cancer therapy. The company will present clinical data to support the biomarker application.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

About Tozaride
Tozaride is a novel, best-in-class cancer therapy based on a radio-labeled somatostatin peptide analogue. Early clinical studies of Tozaride demonstrated that it is well tolerated and may produce prolonged stable disease and improved overall survival in advanced lung cancer patients whose disease has continued to progress after failing other therapies. Tozaride targeted radiotherapy represents a new treatment paradigm which is expected to yield significant clinical benefit for both lung cancer (SCLC, NSCLC), and pancreatic cancer patients. Along with its companion diagnostic that helps identify patients most likely to respond – those with enough expression of the peptide’s target – Tozaride could provide another treatment option for patients who are not eligible for, or who have not responded to current therapies.

On April 25, 2019 Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, reported that the company will host a conference call and live webcast on Thursday, May 2, 2019 at 8:00 a.m. ET to report its first quarter 2019 financial results and other business highlights (Press release, Agios Pharmaceuticals, APR 25, 2019, http://investor.agios.com/news-releases/news-release-details/agios-webcast-conference-call-first-quarter-2019-financial [SID1234535412]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast can be accessed under "Events & Presentations" in the Investors section of the company’s website at www.agios.com. The conference call can be accessed by dialing 1-877-377-7098 (domestic) or 1-631-291-4547 (international) and referring to conference ID 9573049. The webcast will be archived and made available for replay on the company’s website beginning approximately two hours after the event.

On April 25, 2019 Amgen (NASDAQ: AMGN) reported that it will report its first quarter financial results on Tuesday, April 30, 2019, after the close of the U.S. financial markets (Press release, Amgen, APR 25, 2019, View Source [SID1234535408]). The announcement will be followed by a conference call with the investment community at 2 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen’s senior management team.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Live audio of the conference call will be simultaneously broadcast over the internet and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen’s business given by management at certain investor and medical conferences, can be found on Amgen’s website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen’s Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event